GlassScriptPhysician profile
Heather R Bragg
NPI 1992181226
$7,428.98
in general payments reported to CMS, 2019-2025
40 companies · $1,866 in 2025
The $1,866 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,020 · 2022: $288 · 2023: $735 · 2024: $1,520 · 2025: $1,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,120.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $964.89 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $808.20 | 2021-2025 | Caplyta |
| Lundbeck LLC | $707.84 | 2021-2025 | Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $474.01 | 2023-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $409.60 | 2021-2025 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $358.01 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $350.18 | 2021-2025 | Invega Sustenna |
| Alkermes, INC. | $323.76 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Lilly USA, LLC | $300.46 | 2021 | |
| Novo Nordisk INC | $251.54 | 2021 | |
| Corium, LLC | $192.64 | 2023-2024 | Azstarys |
| Biohaven Pharmaceuticals, INC. | $187.86 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $180.93 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Astellas Pharma US INC | $166.01 | 2021 | |
| Glaxosmithkline, LLC. | $162.30 | 2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Bragg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.